Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's inv...
Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
New Capabilities Will Further Extend GeneXpert System Technology Advantages
SUNNYVALE, Calif., June 10 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced that it has received a notice of grant award from the National Institute of Allergy and Infectious Diseases to develop
Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease
MORGANTOWN, W.Va., May 27 /PRNewswire-USNewswire/ -- The Blanchette Rockefeller Neurosciences Institute (BRNI) and Inverness Medical Innovations, Inc. (Inverness, NYSE: IMA ) of Waltham, Massachusetts, a global leader in rapid diagnostics and health management, announced today that they will work...
Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
OXFORD, England, May 18 /PRNewswire/ --
- New Alliance a Key Step for OBT to Broaden its Exciting Pipeline of
Oxford BioTherapeutics (OBT) today announced a strategic alliance with
GlaxoSmithKline to discover, develop
and commercialise novel, therapeutic
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Companies Committed to Investing in New Product Presentations for Patients
SAN DIEGO and INDIANAPOLIS, April 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced that the companies have agreed in principle to the ...
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) inf...
MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop
products for the study of liver stem cells and liver cancer.
Certification Commission for Healthcare Information Technology to Develop Dermatology-Specific Functionality Criteria for Electronic Health Record (EHR) Technology
New Criteria to Help Facilitate EHR Adoption in Small, Ambulatory Physician Practices
SCHAUMBURG, Ill., March 3 /PRNewswire-USNewswire/ -- The Certification Commission for Healthcare Information Technology (CCHIT(R)), the federally recognized body for testing and certifying electronic healt...
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
CHADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it has signed two research collaboration agreements to develop
novel treatments for pain and to discover potential treatments for cancer.
The first collaboration, with Harvar...
U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq:
VICL) today announced that the Naval Medical Research Center (NMRC) plans
to conduct preclinical and Phase 1 evaluation of a dengue DNA vaccine
formulated with the company's Vaxfectin(R) adjuvant and delivered with the
InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
BILTHOVEN and AMSTERDAM, The Netherlands, October 30 /PRNewswire/ --
InteRNA Technologies B.V. and VU university medical center in Amsterdam,
VUmc, announce today the signing of a framework research agreement to
develop microRNA (miRNA)-based diagnostics and therapeutics for cancer
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
STOCKHOLM, October 2 /PRNewswire/ -- Athera Biotechnologies AB and Dyax
Corp. (NASDAQ: DYAX ) announced today that they have entered into a
collaboration to discover and to develop
therapeutic products for the
prevention or treatment of cardiovascular inflammatory diseases.
Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals,
Inc. (Nasdaq: IDEV ) today announced that it has signed a development,
license and commercialization agreement with Teva Pharmaceutical Industries
Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously
AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease with AMT's Proprietary Gene Therapy Platform
AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ --
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of
human gene therapy, today announced that it obtained a license from Amgen
to use their GDNF gene for the development of a gene therapy treatment for
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ --
Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they
have entered into a global agreement to develop
and commercialize UNBS
5162, one of Unibioscreen's investigational drug and potential breakthrough
Researchers at Axial Biotech Develop a DNA Test for Scoliosis
Study results presented at the Scoliosis Research Society Meeting in Salt Lake City
SALT LAKE CITY, Sept. 11 /PRNewswire/ -- Researchers at Axial Biotech,
Inc., announced today that they have identified specific genetic markers
for scoliosis. The data from this res...
AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
SINGAPORE, Aug. 15 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN )
today announced an innovative new partnership with the National Cancer
Centre Singapore (NCCS) and the National University Hospital (NUH) to
develop anti-cancer compounds. The collaboration, which is spelt out in a
ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
FREDERICK, Md., July 29 /PRNewswire/ -- ImQuest BioSciences announced
today the successful acquisition of funding from the National Institute of
Allergy and Infectious Disease (NIAID/NIH) to support the development of
pyrimidinedione inhibitors as topical microbicides to prevent the sexual
Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
Collaboration Will Seek to Identify Unique microRNA Signatures That Will Predict Risk of Recurrence in Lung Cancer Patients
The Project Will Leverage Rosetta Genomics' Proprietary microRNA Extraction
and Quantification Technologies, and M. D. Anderson's Extensive Know-How ...
Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
- Results from Gene Identification Studies Presented at ASCO Support
Further Exploration of Possible Tests to Predict Response to Targeted Therapies for Colon and Breast Cancers -
REDWOOD CITY, Calif., May 31 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX ), ...
UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism
GROUNDBREAKING RESEARCH PROVIDES EVEN MORE SCIENCE SUPPORTING THE
THEORY THAT VACCINES CAN AND DO CAUSE AUTISM
NIXA, Mo., May 19 /PRNewswire-USNewswire/ -- A primate model for autism
using the U.S. children's immunization schedule was unveiled at the
International Meeting For Autism Resear...
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454
-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today-
MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ --
Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today
announced that Roche has ex...
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/
-- Foamix Ltd, a global leader in the development of dermatological foam
medications and Galderma, a worldwide specialty pharmaceutical company
focused on dermatology, today announced that they have signed an agreement
Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Company's MicroRNA Technology
Tests Will be Developed and Validated Clinically at Clinical Laboratory
Improvement Amendments (CLIA) Certified Laboratory at the University of California, Irvine School of Medicine
Rosetta Genomics Expects Three Tests Applying its MicroRNA Technology to be Developed and...
Velos to Develop Key System Interface for Clinical Research
- Will facilitate tight integration between sponsors and investigators -
FREMONT, Calif., March 26 /PRNewswire/ -- Velos, Inc., a recognized
leader and trusted resource for clinical trial management information
systems and member of the Oracle PartnerNetwork, will work to develop
Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
EMERYVILLE and NOVATO, Calif., March 3 /PRNewswire-FirstCall/ --
Neurobiological Technologies, Inc. (Nasdaq: NTII ) and the Buck Institute
for Age Research (Buck) announced today they have entered into a
collaboration and exclusive license agreement to develop
a novel therapy
for Alzheimer's ...
Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
INCHEON, South Korea, Jan. 10 /PRNewswire/ -- Celltrion, Inc., a Korean
biopharmaceutical company whose core business is currently contract
manufacturing, and CSL Limited, Australia's leading biopharmaceutical
company, announced today the signing of an agreement for the development
and supply ...
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an
RNA interference (RNAi)-based therapeutics developer, announced today that
it has entered into a collaboration and license agreement with Pfizer Inc.
and commercialize its Hepatitis C virus (HCV) compound, TT-033...
GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
* Collaboration aimed at enabling vaccine production facility commissioning in half the time of a traditional egg-based facility.
* Once established, such a vaccine facility could allow manufacturing of
pandemic flu vaccine to commence within 12 weeks of the strain isolation
Raydiance Collaborates With Rutgers University and Nation's Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
Scientists Leveraging Precision and Power of Raydiance USP Laser Platform
to Separate Skin Layers Without Collateral Damage; Decontaminate Tissue; Speed Tissue Cleaning
Initial Proof of Concept Testing Successful During Feasibility Trials
PETALUMA, Calif. and NEW BR...
Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos
New technology developed by researchers at Reproductive Medicine Associates
of New Jersey awarded General Program Prize Paper at American Society for Reproductive Medicine Annual Meeting
WASHINGTON and MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Researchers at
Surgeons Develop Innovative Life-Saving Treatments to Correct Massive Bleeding in Trauma Patients
NEW ORLEANS, Oct. 9 /PRNewswire-USNewswire/ -- Surgeons are testing new
ways of treating the number-one cause of death from trauma in this country
-- massive bleeding. Investigators from Massachusetts General Hospital,
Boston, are deeply cooling the entire body to prolong the time surgeons
Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
PORTLAND, Ore., Oct. 3 /PRNewswire/ -- Virogenomics, Inc. today
announced that the company has been awarded a $2 million grant from the
National Institute of Standards and Technology (NIST) to develop
System on Panel (SSOP) that tests for many different biological markers in
a single ...
Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company's Anthrax Therapeutic
PINE BROOK, N.J., Sept. 25 /PRNewswire/ -- Elusys Therapeutics, Inc.
(Elusys), a privately held biopharmaceutical company developing
antibody-based therapies for the treatment of life-threatening infectious
diseases, today announced it has been awarded a contract for $12 million
for advanced d...
Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
SUNNYVALE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq:
CPHD) today announced the termination of its contract with the Centers for
Disease Control and Prevention (CDC) for development of a rapid
point-of-care diagnostic to detect influenza viruses A and B, and the H5N1
U. of Md. Researchers to Develop Devices to Revolutionize Drug Research
COLLEGE PARK, Md., Sept. 18 /PRNewswire-USNewswire/ --- A
multi-disciplinary group of researchers from the University of Maryland,
College Park, and the University of Maryland Biotechnology Institute (UMBI)
has won a competitive, $2 million National Science Foundation (NSF) grant
LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
BOZEMAN, Mont., Sept. 18 /PRNewswire/ -- LigoCyte Pharmaceuticals,
Inc., today announced a strategic partnership with Biogen Idec (Nasdaq:
BIIB) to develop
therapies targeting CD103 for the treatment of chronic
inflammatory diseases including potential respiratory, gastrointestinal,
Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
Tallahassee Dermatologist Encourages Regular Skin Examinations
TALLAHASSEE, Fla., Sept. 12 /PRNewswire/ -- Once every two hours a
Florida resident is diagnosed with a new case of melanoma skin cancer,
according to the American Cancer Society. A local dermatologist is working
to decrease t...
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the
development of a novel and proprietary orally-administered compound,
SB1518, for the treatment of myeloproliferative disorders (MPD) and certain
hematological malignancies. MPD is believed to be caused by a specific
Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
San Diego Dermatologist Promoting Regular Skin Examinations
SAN DIEGO, Aug. 27 /PRNewswire/ -- Once every ninety minutes a
California resident is diagnosed with a new case of melanoma skin cancer,
according to the American Cancer Society. A local dermatologist is working
to decrease this...